A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

Recruiting now · Not applicable

Conditions studied: Renal Anemia of Chronic Kidney Disease

In brief

For patients with renal anemia treated with hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), there is a clinical need of switching to long-acting and safe medications. Pegmolesatide, a polyethylene glycol (PEG)-conjugated erythropoiesis-stimulating peptide, is a long-acting erythropoiesis-stimulating agent (ESA) with sustained activity. It was approved for marketing by the National Medical Products Administration (NMPA) in June 2023. Phase III clinical trials have demonstrated its efficacy and safety in dialysis patients with renal anemia who were previously treated with recombinant human erythropoietin (rHuEPO). However, there are currently no data regarding the efficacy and safety of switching from HIF-PHIs to pegmolesatide, and there is a lack of standard for the dose conversion. This study is a multi-center, prospective, open-label, randomized parallel-controlled clinical trial, planning to enroll 96 patients. All enrolled patients will receive 12 weeks of treatment and be followed up for 16 weeks.

Key facts

Study ID

NCT07136792

Run by

Guangdong Provincial People's Hospital

People needed

96

Starts

2025-09-08

Expected to finish

2027-12-01

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age between 18-75 years, regardless of gender;
• Body weight ≥ 45 kg, and body mass index (BMI) ≥ 18.5 kg/m²;
• Diagnosis of chronic renal failure, and having undergone a stable regimen of peritoneal dialysis or hemodialysis for at least 12 weeks prior to enrollment (with stable hemofiltration at a frequency of every 2 or 4 weeks if applicable). Stable dialysis frequency and no plans to change the dialysis modality during the trial;
• An up to standard dialysis adequacy testing result before randomization: spKt/V ≥ 1.2 for hemodialysis, Kt/V ≥ 1.7 for peritoneal dialysis;
• Roxadustat dose ≤ 360 mg/week within 4 weeks before randomization, with stable dose; [Stable dose is defined as: (the maximum weekly dose within 4 weeks before randomization - the average weekly dose within 4 weeks before randomization) ÷ the maximum weekly dose within 4 weeks before randomization ≤ 30%];
• Two pre-dialysis HB test values within 4 weeks before randomization of 8.0 - 12.0 g/dl, with an absolute difference between the two Hb values ≤ 1.3 g/dl, and an interval of ≥ 7 days between the two HB tests;
• Serum ferritin level ≥ 100 μg/L and transferrin saturation (TAST) ≥ 20% at the time of testing before randomization, serum folate ≥ the lower limit of normal, and vitamin B12 ≥ the lower limit of normal;
• Understanding of the study procedures and voluntary signing of the written informed consent form.

You may not qualify if…

• Known autoimmune diseases, hematologic disorders (including congenital and acquired conditions such as thalassemia, Fanconi anemia, pure red cell aplasia, myelodysplastic syndrome, hemolytic anemia, and coagulation disorders), or other causes of anemia apart from CKD (such as gastrointestinal bleeding or hookworm disease).
• Confirmed diagnosis of acquired immunodeficiency syndrome (AIDS), syphilis, or tuberculosis and currently undergoing treatment.
• Known allergy to iron agents or polyethylene glycol molecules.
• Treatment history with ESAs in combination with HIF-PHIs drugs within 8 weeks prior to randomization.
• Underwent red blood cell or whole blood transfusion within 12 weeks prior to randomization.
• Poorly controlled blood pressure (uncontrolled hypertension is defined as: during the screening period, systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg in two or more blood pressure measurements, or although the blood pressure values are below the aforementioned criteria, the investigator deems it necessary to adjust antihypertensive medications).
• Active hepatitis or any of the following abnormal test results during the screening period (ALT ≥ 2 times the upper limit of normal, AST ≥ 2 times the upper limit of normal, DBIL ≥ 2 times the upper limit of normal, serum albumin < 2.5 g/dl).
• Participants judged by the investigator to have uncontrolled or symptomatic secondary hyperparathyroidism, or those with blood iPTH > 800 pg/mL during the screening period.
• C-reactive protein ≥ 30 mg/L during the screening period.
• Cardiac function assessed as NYHA Class III or IV during the screening period.
• Pregnant or breastfeeding women, or those planning to become pregnant during the study period.
• Participants who plan to undergo kidney transplantation during the trial period or have already been kidney donors, or those who plan to undergo elective surgery during the trial period.
• Participants deemed by the investigator to have any other factors that make them unsuitable for participation in this trial.

Where it is running

• Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)
• Longyan First Hospital — Longyan, Fujian, China
• Zhangzhou Municipal Hospital of Fujian Province — Zhangzhou, Fujian, China
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China
• The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China
• Meizhou People's Hospital — Meizhou, Guangdong, China
• The First Affiliated Hospital of Shantou University Medical College — Shantou, Guangdong, China
• Yuebei People's Hospital — Shaoguan, Guangdong, China
• Zhongshan Hospital of Traditional Chinese Medicine — Zhongshan, Guangdong, China
• Affiliated Hospital of Zunyi Medical University — Zunyi, Guizhou, China
• Jingmen Central Hospital — Jingmen, Hubei, China
• CNPG Dongfeng General Hospital — Shiyan, Hubei, China
• Wuhan Fourth Hospital — Wuhan, Hubei, China
• Changsha Central Hospital — Changsha, Hunan, China
• Nantong First People's Hospital — Nantong, Jiangsu, China
• The First Hospital of China Medical University — Shenyang, Liaoning, China
• The First Affiliated Hospital of Baotou Medical College — Baotou, Neimenggu, China
• The First Affiliated Hospital of Shandong First Medical University — Jinan, Shandong, China
• Yibin First People's Hospital — Yibin, Sichuan, China
• Tianjin First Center Hospital — Tianjin, Tianjin Municipality, China
• Hangzhou Xiaoshan First People's Hospital — Hangzhou, Zhejiang, China
• The Affiliated People's Hospital of Ningbo University — Ningbo, Zhejiang, China
• Beijing Hospital — Beijing, Beijing Municipality, China
• Rui'an People's Hospital — Wenzhou, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.